XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
  Parkinson's
   Rotenone
  Dementia
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Parkinson's Channel
subscribe to Parkinson's newsletter

Latest Research : Aging : Parkinson's

   DISCUSS   |   EMAIL   |   PRINT
G2019S mutation is major cause of Parkinson's in Ashkenazi Jewish patients
Jan 26, 2006, 16:42, Reviewed by: Dr. Priya Saxena

"Like the discovery of the BRCA1 and BRCA2 gene mutations for breast cancer, this finding will directly affect the way Parkinson's disease is diagnosed in Ashkenazi Jews"

 
Researchers at the Albert Einstein College of Medicine of Yeshiva University and its Manhattan hospital affiliate, Beth Israel Medical Center, have found that a specific mutation in a single gene is a major cause of Parkinson's disease among Ashkenazi (Eastern European) Jews. The report will appear in the January 26 issue of The New England Journal of Medicine.

"Like the discovery of the BRCA1 and BRCA2 gene mutations for breast cancer, this finding will directly affect the way Parkinson's disease is diagnosed in Ashkenazi Jews," says Dr. Susan B. Bressman, senior investigator of the report, who also is Chairperson of Neurology at Beth Israel, as well as Professor and Vice Chair of Neurology at Einstein. "It also emphasizes the benefit of focusing genetic studies in a specific ethnic group, even with regard to a disease not thought to be primarily genetic in origin,"

"Up until now, genetic counseling for Parkinson's disease hasn't really been considered," adds study co-author Dr. Laurie J. Ozelius, Associate Professor of Molecular Genetics at Einstein. "Our finding should bring genetic counseling for Parkinson's disease to the forefront along with genetic testing for early detection of Parkinson's disease."

The researchers focused on a gene called LRRK2, which is mutated in about 1% of late-onset non-familial cases of Parkinson's disease in those patients who are primarily of European ancestry.

Their study involved 120 unrelated Ashkenazi Jewish Parkinson's disease patients who had been seen as outpatients at Beth Israel's neurology department and screened for the gene. For comparison, a control group of 317 Ashenazi Jews who did not have Parkinson's disease was also studied. DNA was extracted from white blood cells or cheek cells of all the study participants and analyzed for mutations.

The G2019S mutation--the most common of several possible LRRK2 mutations--was detected in 18.3 percent (22 out of 120) of the Ashkenazi Jewish Parkinson's patients compared with only 1.3 percent (4 out of 317) of control patients.

The mutation's role was even more dramatic when the 120 Parkinson's disease patients were divided into those (37) with a family history of the disease (defined as having at least one affected first, second, or third degree relative) and those (83) with no family history. The G2019S mutation was found in 29.7 percent (11/37) of the familial Parkinson's cases but also in 13.3 percent (11/83) of so-called sporadic or nonfamilial cases. The frequency of this mutation among Ashkenazi Parkinson's patients was 15 to 20 times higher than has been reported among patients of European ancestry in general.

In addition to Ashkenazi Jews, the researchers note that a group of North Africans of Arab descent have been found to have a high frequency of this same gene mutation as a cause of Parkinson's disease. The two groups appear to share the same origin or founder, suggesting a probable Middle Eastern origin for this mutation.
 

- January 26 issue of The New England Journal of Medicine
 

www.aecom.yu.edu

 
Subscribe to Parkinson's Newsletter
E-mail Address:

 

Funding for the study was provided by the Edwin and Caroline Levy Foundation, the Michael J. Fox Foundation for Parkinson's Research, the Thomas Hartman Foundation for Parkinson's Research Inc. and the National Institutes of Health.

In addition to Drs. Bressman and Ozelius, authors on the paper included: Geetha Senthil, Ph.D., Rachel Saunders-Pullman, M.D. M.P.H., Erin Ohmann,B.S., Amanda Deligtisch, M.D., Michele Tagliati, M.D., Ann L. Hunt, D.O., Christine Klein, M.D., Brian Henick, Susan M. Hailpern, M.S., M.P.H., Richard B. Lipton, M.D., Jeannie Soto-Valencia, B.A. and Neil Risch, Ph.D.


Related Parkinson's News

Laser probe of a brain pigment's anatomy may offer insight into Parkinson's disease
Novel blood test for early detection of Parkinson's, receives national recognition
New genetic model for Parkinson's disease
Expertise In Brain Stimulation Therapy May Improve Outcomes in Parkinson's Disease
Pesticide Dieldrin Linked to Increased Risk of Parkinson's Disease
ER trafficking defect caused by alpha-synuclein accumulation implicated in Parkinson's
Pesticides exposure associated with Parkinson's disease
Tuberculosis drug PAS may cure Parkinson's-like illness
Stabilizing microtubules with L-AP4 reduces rotenone toxicity
New Guidelines Improve Diagnosis and Quality of Life for People with Parkinson Disease


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us